The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas

Shen, Qi; Li, Shu; Luo, Hui; Hu, Xiaoli; Zhu, Xueqiong

doi:10.1097/md.0000000000006680

Cited by 4 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, we found that the history of induced abortions significantly increased the risk of UL in the study sample (OR adj = 2.78). Our results support the recent findings by other researchers (Shen et al, 2017;Song et al, 2017). Induced abortions are common birth control method in Russia (and generally in the former USSR) (Sedgh et al, 2007;David et al, 2007;Douglas et al, 2014), and Russia (along with Cuba) is a leader by this indicator in the world (Sedgh et al, 2007).…”

Section: Discussionsupporting

confidence: 92%

Candidate Genes for Age at Menarche Are Associated With Uterine Leiomyoma

et al. 2021

View full text Add to dashboard Cite

Age at menarche (AAM) is an important marker of the pubertal development and function of the hypothalamic–pituitary–ovarian system. It was reported as a possible factor for a risk of uterine leiomyoma (UL). However, while more than 350 loci for AAM have been determined by genome-wide association studies (GWASs) to date, no studies of these loci for their association with UL have been conducted so far. In this study, we analyzed 52 candidate loci for AAM for possible association with UL in a sample of 569 patients and 981 controls. The results of the study suggested that 23 out of the 52 studied polymorphisms had association with UL. Locus rs7759938 LIN28B was individually associated with the disease according to the dominant model. Twenty loci were associated with UL within 11 most significant models of intergenic interactions. Nine loci involved in 16 most significant models of interactions between single-nucleotide polymorphism (SNP), induced abortions, and chronic endometritis were associated with UL. Among the 23 loci associated with UL, 16 manifested association also with either AAM (7 SNPs) or height and/or body mass index (BMI) (13 SNPs). The above 23 SNPs and 514 SNPs linked to them have non-synonymous, regulatory, and expression quantitative trait locus (eQTL) significance for 35 genes, which play roles in the pathways related to development of the female reproductive organs and hormone-mediated signaling [false discovery rate (FDR) ≤ 0.05]. This is the first study reporting associations of candidate genes for AAM with UL.

show abstract

Section: Discussionsupporting

confidence: 92%

Candidate Genes for Age at Menarche Are Associated With Uterine Leiomyoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To avoid the risks of surgical intervention, many novel therapies are currently under investigation. At present, medical interventions used to manage uterine fibroids include mifepristone [ 6 , 7 ], ulipristal acetate [ 8 ] and GnRH-agonists. Nevertheless, uterine fibroids will re-grow fast after the cessation of mifepristone treatment and the duration of treatment with GnRH-agonists is limited by the induction of hypoestrogenic symptoms [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

The role of atorvastatin in suppressing tumor growth of uterine fibroids

Shen

Sheng

et al. 2018

J Transl Med

Self Cite

View full text Add to dashboard Cite

BackgroundMedical therapeutic options remain quite limited for uterine fibroids treatment. Statins, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, have anti-tumoral effects on multiple cancer types, however, little is known about their effects on uterine fibroids.MethodsInitially, we conducted a retrospective study of 120 patients with uterine fibroids and hyperlipidemia from the Second Affiliated Hospital of Wenzhou Medical University. Then, we evaluated the effect of atorvastatin on proliferation and apoptosis both in immortalized uterine fibroids cells and primary uterine fibroids cells. Furthermore, the molecular mechanism by which atorvastatin suppressed uterine fibroids cell growth was explored.ResultsOur results showed that atorvastatin use for 1 or 2 years significantly suppressed growth of uterine fibroids. Atorvastatin inhibited the proliferation of immortalized and primary uterine fibroids cells in a dose and time-dependent manner and stimulated apoptosis of uterine fibroids cells by inducing caspase-3 activation, up-regulating Bim and down-regulating Bcl-2. Additionally, atorvastatin treatment suppressed phosphorylation of ERK1/2 and JNK. Furthermore, GGPP, a downstream lipid isoprenoid intermediate, significantly rescued the effect of atorvastatin.ConclusionsThese results suggest that atorvastatin exerts anti-tumoral effects on uterine fibroids through inhibition of cell proliferation and induction of apoptosis in HMG-CoA-dependent pathway. Our results provide the first clinical and preclinical data on the use of atorvastatin as a promising nonsurgical treatment option for uterine fibroids.

show abstract

“…As regard endometrial thickness there was no statistically significant difference between three groups after 6 months of treatment. Table (5) shows that as regard cholesterol level there was statistically significant difference between the three groups after 6 months of treatment. There was statistically significant difference between (group A and B), (group A and control group) and (group B and control group) after 6 months.…”

Section: Resultsmentioning

confidence: 87%

“…At present, medical interventions used to manage uterine fibroids include mifepristone, ulipristal acetate, and GnRH-agonists. Nevertheless, uterine fibroids will regrow fast after the cessation of mifepristone, and the duration of treatment with GnRH-agonists is limited by the induction of hypoestrogenic symptoms (3)(4)(5) .…”

Section: Introductionmentioning

confidence: 99%

The Role of Atorvastatin in Suppressing Fibroid Related Symptom and Fibroid Size in Perimenopausal Women

Seada¹,

Elmorsy²,

Fayala³

et al. 2021

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Uterine fibroids are the most common benign gynecologic tumors, with a lifetime incidence of approximately 70%. They are associated with multiple symptoms, including heavy uterine bleeding and pelvic pain. Currently used treatments include contraceptive steroids, Gonadotropin-releasing hormone agonist (GnRHa), progesterone modulators, uterine artery embolization (UAE), magnetic resonance imaging-guided focused ultrasound surgery (MRgFUS), and radiofrequency ablation (RFA). Objective: To evaluate the effect of atorvastatin on decreasing fibroid related symptoms and fibroid size, endometrial thickness and cholesterol level in perimenopausal women. Patients and methods: Prospective randomized controlled trial that was conducted over a period of 12 months during 2019 and 2021 on 105 patients with symptomatic uterine fibroid in perimenopausal age, admitted to emergency unit and gynecology outpatient clinic at Mansoura University Hospital and after obtaining acceptance from institutional research board faculty of medicine then patients were prospectively recruited and randomized by computer program. Results: All groups at presentation demonstrated insignificant differences concerning demographic characteristics, gravidity and symptoms of uterine fibroid. Uterine fibroid demonstrated significant reduction in size as well as significant changes following the atorvastatin treatment after 6 months in a dose dependent manner, while endometrial thickness demonstrated insignificant differences as measured by transvaginal ultrasound (TVS). Cholesterol level demonstrated highly statistically significant decrease following atorvastatin treatment in a dose dependent manner. Conclusion:The current study demonstrated that atorvastatin has promising effects in cases with uterine fibroids as it was associated with a reduction of fibroid size with reduction of fibroid related symptom (menorrhagia, dysmenorrhea).

show abstract

The use of mifepristone in abortion associated with an increased risk of uterine leiomyomas

Cited by 4 publications

References 29 publications

Candidate Genes for Age at Menarche Are Associated With Uterine Leiomyoma

Candidate Genes for Age at Menarche Are Associated With Uterine Leiomyoma

The role of atorvastatin in suppressing tumor growth of uterine fibroids

The Role of Atorvastatin in Suppressing Fibroid Related Symptom and Fibroid Size in Perimenopausal Women

Contact Info

Product

Resources

About